Rasonque moves closer to EU approval for pancreatic cancer, halving the risk of death
Europe's medicines committee has backed the drug after its Phase 3 trial showed median survival of 13.2 months versus 6.7 months on chemotherapy. A final European Commission decision is still pending.
2 min read